1-9 of 9
Harald Holte, Jr., MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

Lasse H. Jakobsen, Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob H. Christensen, Judit Jørgensen, MD PhD, Pär L. Josefsson, Harald Holte, Jr., MD PhD, Yngvild N. Blaker, Jacob H. Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, MD, Karin Ekstroem Smedby, MDPhD, Katherine Colvin, Gita Thanarajasingam, MD, Alina S. Gerrie, MD MPH, Chan Y. Cheah, Tarec C. El-Galaly
Journal: Blood
Blood (2018) 132 (Supplement 1): 452.
https://doi.org/10.1182/blood-2018-99-111748
Published: 2018
Journal Articles

Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients

Jorne Lionel Biccler, MSc, BSc, Ingrid Glimelius, MD PhD, Sandra Eloranta, Knut B. Smeland, Peter de Nully Brown, MD PhD, Lasse H. Jakobsen, Henrik Frederiksen, MD PhD, Mats Jerkeman, Alexander Fosså, MD PhD, Therese M.L. Andersson, PhD, Harald Holte, Jr., MD PhD, Martin Bøgsted, Professor, Tarec C. El-Galaly, Karin Ekstroem Smedby, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 930.
https://doi.org/10.1182/blood-2018-99-111759
Published: 2018
Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hajek, MD PhD, Wojciech Jurczak, MD PhD, Ella Willenbacher, MD, Unn Merete Fagerli, MD PhD, Aleš Obr, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Åse Østengen, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2879.
https://doi.org/10.1182/blood-2018-99-110555
Published: 2018
Journal Articles

Low Expression and Somatic Mutations of the KLHL6 Gene Predict Poor Survival in Patients with Activated B-Cell like Diffuse Large B-Cell Lymphoma

Leo Meriranta, MS, Annika Pasanen, MD PhD, Alejandra Cervera, MSc, Harald Holte, Jr., MD PhD, Rainer Lehtonen, PhD, Sampsa Hautaniemi, Professor, Sirpa Leppä, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2926.
https://doi.org/10.1182/blood.V128.22.2926.2926
Published: 2016
Journal Articles

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

Dag Josefsen, MD PhD, Yngvar Fløisand, MD PhD, Harald Holte, Jr., MD PhD, Gunnar Kvalheim, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5826.
https://doi.org/10.1182/blood.V128.22.5826.5826
Published: 2016
Journal Articles

Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-Cell Lymphoma

Jillian Frances Wise, PhD, Sigve Nakken, PhD, Daniel Vodak, BS, Gunhild Trøen, PhD, Ole Christian Lingjærde, PhD, Leonardo A. Meza-Zepeda, PhD, Ola Myklebost, PhD, Klaus Beiske, MD PhD, June Helen Myklebust, PhD, Eivind Hovig, PhD, Erlend Smeland, MD PhD, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2015) 126 (23): 110.
https://doi.org/10.1182/blood.V126.23.110.110
Published: 2015
Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2015) 126 (23): 5118.
https://doi.org/10.1182/blood.V126.23.5118.5118
Published: 2015
Journal Articles

Alternative Splicing and Expression of Class II Tubulin Beta ( TUBB2B ) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

Minna Taskinen, PhD, Satu Koivula, MSc, Ping Chen, MSc, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Alejandra Cervera, MSc student, Jan Delabie, Harald Holte, Jr., MD, PhD, Sampsa Hautaniemi, Sirpa Leppä
Journal: Blood
Blood (2012) 120 (21): 1557.
https://doi.org/10.1182/blood.V120.21.1557.1557
Published: 2012
Journal Articles

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Eva Kimby, M.D., Ph.D., Björn Östenstad, Peter de Nully Brown, Harald Holte, Jr., MD, PhD, Hans Hagberg, Martin Erlanson, Ola Linden, MD, Marie Nordström, MD, PhD, Christer Sundstrom, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 794.
https://doi.org/10.1182/blood.V120.21.794.794
Published: 2012